The global preimplantation genetic testing (PGT) market was valued at approximately USD 802.2 million in 2023 and is projected to expand at a compound annual growth rate (CAGR) of 10.3% from 2024 to 2030. Several factors are contributing to this growth, notably the rising prevalence of genetic disorders such as single gene, mitochondrial, and other hereditary conditions. As awareness of genetic risks increases, there is a growing demand for preimplantation diagnosis and screening processes to ensure healthier pregnancies and reduce the risk of passing on genetic diseases.

For example, the Florida Department of Health reports that one in every 33 babies in the U.S. is born with a congenital disability, which affects approximately 120,000 babies each year. These statistics highlight the importance of genetic testing, as more families seek options to prevent the transmission of such disorders. As advancements in genetic testing continue, the demand for preimplantation genetic testing is expected to increase. For instance, in July 2023, Thermo Fisher Scientific Inc. launched two new Next-Generation Sequencing (NGS)-based tests specifically designed for preimplantation genetic testing for aneuploidy (PGT-A). This addition reflects the continued innovation in the field and its potential to drive market growth in the coming years.

Preimplantation genetic diagnosis (PGD) plays a critical role in the in vitro fertilization (IVF) process, particularly for individuals or couples with a history of miscarriages or those who have experienced pregnancies involving chromosomal abnormalities. PGD is typically used in IVF cycles to help ensure a successful pregnancy by identifying embryos that do not carry genetic disorders or chromosomal abnormalities. This testing is especially beneficial for couples who are at risk for hereditary genetic disorders, offering them a chance to have a healthy child and preventing the transmission of genetic diseases.

Gather more insights about the market drivers, restrains and growth of the Preimplantation Genetic Testing Market

Regional Insights

North America accounted for a significant share of the global preimplantation genetic testing (PGT) market, driven by a combination of factors such as the rising prevalence of various genetic disorders, increasing number of laboratories offering PGT services, and heightened awareness of genetic screening. The market is also buoyed by a high incidence of hereditary disorders and other common diseases, such as Polycystic Ovary Syndrome (PCOS) and chlamydia, which further increase the demand for genetic testing. The adoption of advanced reproductive technologies, such as in-vitro fertilization (IVF) with PGT to prevent genetic disorders, has significantly contributed to the growth in this region.

U.S. 

In the United States, the PGT market is witnessing steady growth, fueled by increasing awareness about hereditary disorders, advancements in reproductive technologies, rising infertility rates, and a growing preference for personalized medicine. Moreover, supportive government regulations and a high demand for IVF procedures have further driven market expansion. As more individuals seek fertility solutions that enable them to have healthy offspring, the demand for PGT services is expected to increase, contributing to the overall growth of the market in the U.S.

Europe 

Europe dominated the global PGT market in 2023, accounting for 40.74% of the total revenue share. This leadership is primarily driven by a high volume of IVF procedures, which have been increasingly adopted due to the trend of late pregnancies among women in Europe. Additionally, the liberal regulations surrounding aneuploidy screening in many European countries, coupled with the presence of established market players and healthcare providers, are helping to propel the growth of the PGT market in the region.

The UK market for preimplantation genetic testing is also expected to see significant growth due to government policies that support IVF, along with funding initiatives and a rising demand for personalized medicine. These factors, combined with better IVF success rates, will drive the adoption of PGT solutions across the country.

In Germany, the PGT market is set for growth as increasing public awareness about genetic disorders and the benefits of PGT is prompting more couples to opt for genetic testing before pregnancy. As these trends continue, Germany will see continued market expansion.

Asia Pacific 

The Asia Pacific region is poised to register the highest CAGR of 11.3% during the forecast period. This growth is fueled by advancements in reproductive technology, expanding healthcare accessibility, and a greater awareness of PGT across the region. Countries like China and Japan are leading the way in the integration of advanced genetic testing technologies within reproductive health practices, helping to boost the demand for PGT services.

In China, the growing burden of genetic diseases and a large population with significant hereditary disorders are driving the demand for preimplantation genetic testing. With a high adoption rate of IVF procedures, the need for PGT to ensure healthy births by selecting embryos free of genetic mutations is expected to fuel market growth.

Similarly, Japan is seeing increasing demand for PGT due to technological innovations in genetic testing and heightened awareness of the benefits of genetic screening. These factors, combined with an increasing number of couples opting for assisted reproductive technologies, will contribute to the growth of the PGT market in Japan.

Latin America 

The Latin American market for preimplantation genetic testing is expected to experience substantial growth, primarily driven by increasing awareness of genetic disorders. As people become more educated about the risks of hereditary diseases, the demand for proactive genetic testing during family planning is expected to rise.

In Brazil, the market is poised for significant growth due to the entry of new providers and the introduction of advanced genomic technologies. These innovations are enhancing the accuracy and range of conditions that can be screened through PGT, expanding the market's potential in the country.

Middle East and Africa (MEA) 

In the MEA region, the preimplantation genetic testing market is also expected to grow significantly, driven by increasing awareness of the importance of genetic screening and diagnosis. The region has seen a positive shift in attitudes toward hereditary diseases, with more people recognizing the benefits of PGT.

The UAE is experiencing growth in the PGT market, supported by a cultural shift toward acceptance of advanced medical technologies. As social attitudes evolve positively toward genetic testing, Emiratis and expatriates alike are more likely to consider PGT for family planning. This change is further supported by an increasingly progressive healthcare infrastructure that facilitates the adoption of innovative medical technologies.

In Kuwait, technological advancements in hereditary testing technologies are driving the growth of the PGT market. Enhanced accuracy and reliability in genetic testing are contributing to better outcomes for couples undergoing assisted reproductive treatments, thereby boosting demand for PGT services.

Browse through Grand View Research's  Clinical Diagnostics Industry Research Reports.

• The tissue diagnostics market size was estimated at USD 8.72 billion in 2024 and is projected to grow at a CAGR of 8.41% from 2025 to 2030.

• The global ovarian cancer diagnostics market was valued at USD 4.60 billion in 2023 and is expected to grow at a CAGR of 5.0% during the forecast period.

Key Preimplantation Genetic Testing Company Insights

Several key players dominate the global preimplantation genetic testing (PGT) market, including Quest Diagnostics Incorporated, Natera, Inc., and Illumina, Inc. These companies are driving innovation and expanding their reach through a variety of strategies, such as new product launches, strategic acquisitions, and partnerships with healthcare providers.

• Illumina, Inc. is a leading player in the genomics and sequencing industry, providing advanced tools and technologies that enable the accurate analysis of DNA. Their solutions are widely used across healthcare, agriculture, and scientific research, helping to drive advancements in personalized medicine and genetic testing.

• Quest Diagnostics Incorporated is a major medical diagnostics company that offers clinical testing services, including gene-based testing, routine testing, and drugs-of-abuse testing. Their services are critical for healthcare providers, and their global presence, including in Mexico, India, Ireland, and the UK, enhances their capacity to serve diverse markets. Their diagnostic laboratories are key partners in expanding access to PGT and other advanced testing technologies.

Key Preimplantation Genetic Testing Companies:

The following are the leading companies in the preimplantation genetic testing market. These companies collectively hold the largest market share and dictate industry trends.

• Quest Diagnostics Incorporated

• Natera, Inc.

• COOPER SURGICAL, INC.

• Genea Pty Limited.

• Invitae Corporation

• Laboratory Corporation of America Holdings

• Thermo Fisher Scientific Inc.

• Bioarray S.L.

• Illumina, Inc.

• Igenomix

• RGI

• F. Hoffmann-La Roche Ltd

Order a free sample PDF of the Preimplantation Genetic Testing Market Intelligence Study, published by Grand View Research.